One-year outcome in multivessel coronary disease patients undergoing coronary stenting

Stefano De Servi, Giuseppe Mariani, Irene Bossi, Catherine Klersy, Paolo Rubartelli, Luigi Niccoli, Alessandra Repetto, Luigi Giommi, Giovanni Baduini, Aleardo Maresta, Sergio Repetto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this study was to assess 1-year clinical outcome of patients with multivessel coronary artery disease (CAD) who underwent coronary stenting and were prospectively enrolled in the Registro Impianto Stent Endocoronarico (RISE). Of 939 consecutive patients included in the registry, 377 patients with angiographic evidence of multivessel CAD had a 1- year clinical follow-up. All patients underwent PTCA and single or multiple stenting in at least one vessel. Angiographic optimization was usually performed by using high-pressure balloon dilation. After the procedure, continuation of aspirin (at least 250 mg/day) was recommended, whereas the use of anticoagulation or ticlopidine was determined by the physician In charge of the patient in the various centers. Major adverse cardiac events were defined as death, Q-wave or non-Q-wave myocardial infarction and target vessel revascularization. Mean age of patients (311 men, 66 women) was 60 ± 10 years. Globally, there were 596 stents implanted (72% Palmaz-Schatz stents) in 434 vessels. In about 75% of the procedures, an inflation pressure > 12 atm was used. Angiographic success rate was 98.5%. After stenting, 77% of patients received antiplatelet treatment with ticlopidine and aspirin. During hospitalization, there were 34 major adverse cardiac events in 24 patients. At 1-year follow-up, 309 patients were alive and event-free; cumulative incidence of death, myocardial infarction, and repeat revascularization were 2.9%, 4.7%, and 10.8%, respectively. By Cox regression analysis, multiple stents implantation (HR 1.72, 95% Cl 1-2.97), left anterior descending artery revascularization (HR 1.86, 95% CI 1.01-3.42), use of inflation pressure > 12 atm (HR 0.93, 95% CI 0.89-0.97), ticlopidine therapy (HR 0.41, 95% CI 0.23-0.74), and stent length (HR 1.03, 95% CI 1.01- 1.05) were associated with 1-year major cardiac events. In patients with multivessel CAD undergoing stent implantation in at least one vessel, 1-year follow-up is favorable and the need for repeat revascularization procedures, based on clinical data, is lower than previously reported for conventional PTCA.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume48
Issue number4
DOIs
Publication statusPublished - Dec 1999

Fingerprint

Coronary Disease
Stents
Ticlopidine
Coronary Artery Disease
Economic Inflation
Pressure
Aspirin
Myocardial Infarction
Registries
Dilatation
Hospitalization
Arteries
Regression Analysis
Physicians
Incidence
Therapeutics

Keywords

  • Multivessel coronary disease
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

One-year outcome in multivessel coronary disease patients undergoing coronary stenting. / De Servi, Stefano; Mariani, Giuseppe; Bossi, Irene; Klersy, Catherine; Rubartelli, Paolo; Niccoli, Luigi; Repetto, Alessandra; Giommi, Luigi; Baduini, Giovanni; Maresta, Aleardo; Repetto, Sergio.

In: Catheterization and Cardiovascular Interventions, Vol. 48, No. 4, 12.1999, p. 343-349.

Research output: Contribution to journalArticle

De Servi, Stefano ; Mariani, Giuseppe ; Bossi, Irene ; Klersy, Catherine ; Rubartelli, Paolo ; Niccoli, Luigi ; Repetto, Alessandra ; Giommi, Luigi ; Baduini, Giovanni ; Maresta, Aleardo ; Repetto, Sergio. / One-year outcome in multivessel coronary disease patients undergoing coronary stenting. In: Catheterization and Cardiovascular Interventions. 1999 ; Vol. 48, No. 4. pp. 343-349.
@article{28465abb07764ce9b9d6377efbc99c4e,
title = "One-year outcome in multivessel coronary disease patients undergoing coronary stenting",
abstract = "The purpose of this study was to assess 1-year clinical outcome of patients with multivessel coronary artery disease (CAD) who underwent coronary stenting and were prospectively enrolled in the Registro Impianto Stent Endocoronarico (RISE). Of 939 consecutive patients included in the registry, 377 patients with angiographic evidence of multivessel CAD had a 1- year clinical follow-up. All patients underwent PTCA and single or multiple stenting in at least one vessel. Angiographic optimization was usually performed by using high-pressure balloon dilation. After the procedure, continuation of aspirin (at least 250 mg/day) was recommended, whereas the use of anticoagulation or ticlopidine was determined by the physician In charge of the patient in the various centers. Major adverse cardiac events were defined as death, Q-wave or non-Q-wave myocardial infarction and target vessel revascularization. Mean age of patients (311 men, 66 women) was 60 ± 10 years. Globally, there were 596 stents implanted (72{\%} Palmaz-Schatz stents) in 434 vessels. In about 75{\%} of the procedures, an inflation pressure > 12 atm was used. Angiographic success rate was 98.5{\%}. After stenting, 77{\%} of patients received antiplatelet treatment with ticlopidine and aspirin. During hospitalization, there were 34 major adverse cardiac events in 24 patients. At 1-year follow-up, 309 patients were alive and event-free; cumulative incidence of death, myocardial infarction, and repeat revascularization were 2.9{\%}, 4.7{\%}, and 10.8{\%}, respectively. By Cox regression analysis, multiple stents implantation (HR 1.72, 95{\%} Cl 1-2.97), left anterior descending artery revascularization (HR 1.86, 95{\%} CI 1.01-3.42), use of inflation pressure > 12 atm (HR 0.93, 95{\%} CI 0.89-0.97), ticlopidine therapy (HR 0.41, 95{\%} CI 0.23-0.74), and stent length (HR 1.03, 95{\%} CI 1.01- 1.05) were associated with 1-year major cardiac events. In patients with multivessel CAD undergoing stent implantation in at least one vessel, 1-year follow-up is favorable and the need for repeat revascularization procedures, based on clinical data, is lower than previously reported for conventional PTCA.",
keywords = "Multivessel coronary disease, Stents",
author = "{De Servi}, Stefano and Giuseppe Mariani and Irene Bossi and Catherine Klersy and Paolo Rubartelli and Luigi Niccoli and Alessandra Repetto and Luigi Giommi and Giovanni Baduini and Aleardo Maresta and Sergio Repetto",
year = "1999",
month = "12",
doi = "10.1002/(SICI)1522-726X(199912)48:4<343::AID-CCD2>3.0.CO;2-5",
language = "English",
volume = "48",
pages = "343--349",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - One-year outcome in multivessel coronary disease patients undergoing coronary stenting

AU - De Servi, Stefano

AU - Mariani, Giuseppe

AU - Bossi, Irene

AU - Klersy, Catherine

AU - Rubartelli, Paolo

AU - Niccoli, Luigi

AU - Repetto, Alessandra

AU - Giommi, Luigi

AU - Baduini, Giovanni

AU - Maresta, Aleardo

AU - Repetto, Sergio

PY - 1999/12

Y1 - 1999/12

N2 - The purpose of this study was to assess 1-year clinical outcome of patients with multivessel coronary artery disease (CAD) who underwent coronary stenting and were prospectively enrolled in the Registro Impianto Stent Endocoronarico (RISE). Of 939 consecutive patients included in the registry, 377 patients with angiographic evidence of multivessel CAD had a 1- year clinical follow-up. All patients underwent PTCA and single or multiple stenting in at least one vessel. Angiographic optimization was usually performed by using high-pressure balloon dilation. After the procedure, continuation of aspirin (at least 250 mg/day) was recommended, whereas the use of anticoagulation or ticlopidine was determined by the physician In charge of the patient in the various centers. Major adverse cardiac events were defined as death, Q-wave or non-Q-wave myocardial infarction and target vessel revascularization. Mean age of patients (311 men, 66 women) was 60 ± 10 years. Globally, there were 596 stents implanted (72% Palmaz-Schatz stents) in 434 vessels. In about 75% of the procedures, an inflation pressure > 12 atm was used. Angiographic success rate was 98.5%. After stenting, 77% of patients received antiplatelet treatment with ticlopidine and aspirin. During hospitalization, there were 34 major adverse cardiac events in 24 patients. At 1-year follow-up, 309 patients were alive and event-free; cumulative incidence of death, myocardial infarction, and repeat revascularization were 2.9%, 4.7%, and 10.8%, respectively. By Cox regression analysis, multiple stents implantation (HR 1.72, 95% Cl 1-2.97), left anterior descending artery revascularization (HR 1.86, 95% CI 1.01-3.42), use of inflation pressure > 12 atm (HR 0.93, 95% CI 0.89-0.97), ticlopidine therapy (HR 0.41, 95% CI 0.23-0.74), and stent length (HR 1.03, 95% CI 1.01- 1.05) were associated with 1-year major cardiac events. In patients with multivessel CAD undergoing stent implantation in at least one vessel, 1-year follow-up is favorable and the need for repeat revascularization procedures, based on clinical data, is lower than previously reported for conventional PTCA.

AB - The purpose of this study was to assess 1-year clinical outcome of patients with multivessel coronary artery disease (CAD) who underwent coronary stenting and were prospectively enrolled in the Registro Impianto Stent Endocoronarico (RISE). Of 939 consecutive patients included in the registry, 377 patients with angiographic evidence of multivessel CAD had a 1- year clinical follow-up. All patients underwent PTCA and single or multiple stenting in at least one vessel. Angiographic optimization was usually performed by using high-pressure balloon dilation. After the procedure, continuation of aspirin (at least 250 mg/day) was recommended, whereas the use of anticoagulation or ticlopidine was determined by the physician In charge of the patient in the various centers. Major adverse cardiac events were defined as death, Q-wave or non-Q-wave myocardial infarction and target vessel revascularization. Mean age of patients (311 men, 66 women) was 60 ± 10 years. Globally, there were 596 stents implanted (72% Palmaz-Schatz stents) in 434 vessels. In about 75% of the procedures, an inflation pressure > 12 atm was used. Angiographic success rate was 98.5%. After stenting, 77% of patients received antiplatelet treatment with ticlopidine and aspirin. During hospitalization, there were 34 major adverse cardiac events in 24 patients. At 1-year follow-up, 309 patients were alive and event-free; cumulative incidence of death, myocardial infarction, and repeat revascularization were 2.9%, 4.7%, and 10.8%, respectively. By Cox regression analysis, multiple stents implantation (HR 1.72, 95% Cl 1-2.97), left anterior descending artery revascularization (HR 1.86, 95% CI 1.01-3.42), use of inflation pressure > 12 atm (HR 0.93, 95% CI 0.89-0.97), ticlopidine therapy (HR 0.41, 95% CI 0.23-0.74), and stent length (HR 1.03, 95% CI 1.01- 1.05) were associated with 1-year major cardiac events. In patients with multivessel CAD undergoing stent implantation in at least one vessel, 1-year follow-up is favorable and the need for repeat revascularization procedures, based on clinical data, is lower than previously reported for conventional PTCA.

KW - Multivessel coronary disease

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=0032731024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032731024&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1522-726X(199912)48:4<343::AID-CCD2>3.0.CO;2-5

DO - 10.1002/(SICI)1522-726X(199912)48:4<343::AID-CCD2>3.0.CO;2-5

M3 - Article

C2 - 10559809

AN - SCOPUS:0032731024

VL - 48

SP - 343

EP - 349

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 4

ER -